PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG)
Publication
, Conference
Desjardins, A; Chandramohan, V; Landi, D; Peters, K; Johnson, MO; Low, J; Khasraw, M; Threatt, S; Bullock, C; Herndon, J; Lipp, E; Friedman, A ...
Published in: NEURO-ONCOLOGY
2023
Duke Scholars
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2023
Volume
25
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Chandramohan, V., Landi, D., Peters, K., Johnson, M. O., Low, J., … Bigner, D. (2023). PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG). In NEURO-ONCOLOGY (Vol. 25).
Desjardins, Annick, Vidya Chandramohan, Daniel Landi, Katherine Peters, Margaret O. Johnson, Justin Low, Mustafa Khasraw, et al. “PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG).” In NEURO-ONCOLOGY, Vol. 25, 2023.
Desjardins A, Chandramohan V, Landi D, Peters K, Johnson MO, Low J, et al. PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG). In: NEURO-ONCOLOGY. 2023.
Desjardins, Annick, et al. “PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG).” NEURO-ONCOLOGY, vol. 25, 2023.
Desjardins A, Chandramohan V, Landi D, Peters K, Johnson MO, Low J, Khasraw M, Threatt S, Bullock C, Herndon J, Lipp E, Friedman A, Friedman H, Ashley D, Osorio J, Ravetch J, Bigner D. PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG). NEURO-ONCOLOGY. 2023.
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2023
Volume
25
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences